Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Madrigal Pharmaceuticals expands patient access to Resmetirom trial

The company is launching a 52-week active treatment extension study that will continue making the drug available to people with non-alcoholic fatty liver disease. 

By Brian Buntz | July 13, 2021

Madrigal PharmaceuticalsLast month, Madrigal Pharmaceuticals (NSDQ:MDGL) announced promising preliminary results from an open-label Phase 3 trial from its MAESTRO-NAFLD-1 study focused on Resmetirom.

The drug, also known as MGL-3196, appeared to support reducing fat and fibrosis within the liver while also curbing biomarkers associated with inflammation. The data also suggest that the drug reduces LDL cholesterol.

Now, the company has announced a new trial known as MAESTRO-NAFLD-OLE, an open-label active treatment extension study of MAESTRO-NAFLD-1.

The new trial will enable patients who complete MAESTRO-NAFLD-1 to receive resmetirom for 52 additional weeks. Both placebo and previous resmetirom recipients will be eligible to participate.

The MAESTRO-NAFLD-1 study, which involves approximately 1,200 patients, is slated for completion before the end of 2021.

Lancet published positive data from a Phase 2 trial involving resmetirom in 2019.

Madrigal believes that Resmetirom is a first-in-class small-molecule thyroid hormone receptor, a beta-selective agonist.


Filed Under: clinical trials, Drug Discovery
Tagged With: Madrigal Pharmaceuticals, MAESTRO-NAFLD-1, MAESTRO-NAFLD-OLE, MGL-3196, Resmetirom
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50